Skip to main content
Top
Published in: Journal of Medical Case Reports 1/2014

Open Access 01-12-2014 | Case report

An effective 5-fluorouracil, levofolinate, and oxaliplatin therapy for recurrent breast cancer: a case report

Authors: Makoto Takahashi, Koichiro Niwa, Shun Ishiyama, Kiichi Sugimoto, Hiromitsu Komiyama, Yukihiro Yaginuma, Yutaka Kojima, Michitoshi Goto, Atsushi Okuzawa, Yuichi Tomiki, Kazuhiro Sakamoto

Published in: Journal of Medical Case Reports | Issue 1/2014

Login to get access

Abstract

Introduction

Therapy comprising 5-fluorouracil, levofolinate, and oxaliplatin is currently the most common chemotherapy for colorectal cancer. We experienced a successful case of advanced colon cancer and recurrent breast cancer with 5-fluorouracil, levofolinate, and oxaliplatin therapy.

Case presentation

A 43-year-old Japanese woman who had already undergone surgery three times for bilateral breast cancer was admitted to our hospital for the treatment of advanced transverse colon cancer. Preoperative computed tomography demonstrated a swollen lymph node at her right upper clavicle, and fine-needle aspiration biopsy of the lymph node showed that it was a metastasis from the breast cancer. A laparoscopic-assisted colectomy was performed and the pathology demonstrated that the final stage was IIIC (T4aN2aM0, Union for International Cancer Control, 7th edition). The pathological findings and immunohistochemistry showed that the transverse colon tumor was not a metastatic lesion from the breast cancer, but was a de novo colon cancer. Chemotherapy was necessary for both the recurrent breast cancer and the Stage IIIC colon cancer. Therapy of 5-fluorouracil, levofolinate, and oxaliplatin was administered; the therapy included 5-fluorouracil, which is considered to be effective for both colon and breast cancer. After two courses of 5-fluorouracil, levofolinate, and oxaliplatin, the lymph node began to shrink and almost completely disappeared after eight courses of 5-fluorouracil, levofolinate, and oxaliplatin.

Conclusion

We surmise that 5-fluorouracil, levofolinate, and oxaliplatin have the potential to provide a good response for tumors that are sensitive to fluorinated pyrimidine and platinum-containing anticancer drugs such as breast cancer.
Appendix
Available only for authorised users
Literature
2.
go back to reference Union for International Cancer Control: TNM Classification of Malignant Tumours. 2009, UICC–Wiley-Blackwell, 7 Union for International Cancer Control: TNM Classification of Malignant Tumours. 2009, UICC–Wiley-Blackwell, 7
3.
go back to reference U.S. Department of Health and Human Services. National Institutes of Health. National Cancer Institute: Version 4.0. U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE). 2009, National Institutes of Health. National Cancer Institute U.S. Department of Health and Human Services. National Institutes of Health. National Cancer Institute: Version 4.0. U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE). 2009, National Institutes of Health. National Cancer Institute
4.
go back to reference Eisenhauera EA, Therasseb P, Bogaertsc J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther M, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 2009, 45: 228-247.CrossRef Eisenhauera EA, Therasseb P, Bogaertsc J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther M, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 2009, 45: 228-247.CrossRef
5.
go back to reference Saito M: Chemotherapy for breast cancer. Juntendo Med J. 2006, 52: 546-558.CrossRef Saito M: Chemotherapy for breast cancer. Juntendo Med J. 2006, 52: 546-558.CrossRef
6.
go back to reference Ide T, Asahi M, Omori S: The side effect and countermeasure of oral anticancer drugs in breast cancer ambulatory. J Pract Pharm. 2006, 57: 439-445. Ide T, Asahi M, Omori S: The side effect and countermeasure of oral anticancer drugs in breast cancer ambulatory. J Pract Pharm. 2006, 57: 439-445.
7.
go back to reference Shinohara K, Konishi T, Ushirokohji Y, Yoshino G, Yuzumoto S, Sanjo K, Idezuki Y: Biochemically modulated chemotherapy with leucovorin and 5-fluorouracil for metastasis of colorectal cancer. J Jpn Soc Coloproctol. 1992, 45: 336-340.CrossRef Shinohara K, Konishi T, Ushirokohji Y, Yoshino G, Yuzumoto S, Sanjo K, Idezuki Y: Biochemically modulated chemotherapy with leucovorin and 5-fluorouracil for metastasis of colorectal cancer. J Jpn Soc Coloproctol. 1992, 45: 336-340.CrossRef
8.
go back to reference Tamura T: An overview of chemotherapy and current topics for colorectal cancer in Japan. Jpn J Chemother. 2006, 54: 232-238. Tamura T: An overview of chemotherapy and current topics for colorectal cancer in Japan. Jpn J Chemother. 2006, 54: 232-238.
9.
go back to reference Sun S, Wang LP, Zhang J, Yang XY, Zhang QL, Jia Z, Hu XC, Wang BY: Phase II study of oxaliplatin plus leucovorin and 5-fluorouracil in heavily pretreated metastatic breast cancer patients. Med Oncol. 2012, 29: 418-424.CrossRefPubMed Sun S, Wang LP, Zhang J, Yang XY, Zhang QL, Jia Z, Hu XC, Wang BY: Phase II study of oxaliplatin plus leucovorin and 5-fluorouracil in heavily pretreated metastatic breast cancer patients. Med Oncol. 2012, 29: 418-424.CrossRefPubMed
10.
go back to reference Pectasides D, Pectasides M, Farmakis D, Bountouroglou N, Nikolaou M, Koumpou M, Mylonakis N, Kosmas C: Oxaliplatin plus high-dose leucovorin and 5-fluorouracil in pretreated advanced breast cancer: a phase II study. Ann Oncol. 2003, 14: 537-542.CrossRefPubMed Pectasides D, Pectasides M, Farmakis D, Bountouroglou N, Nikolaou M, Koumpou M, Mylonakis N, Kosmas C: Oxaliplatin plus high-dose leucovorin and 5-fluorouracil in pretreated advanced breast cancer: a phase II study. Ann Oncol. 2003, 14: 537-542.CrossRefPubMed
11.
go back to reference Zelek L, Cottu P, Tubiana-Hulin M, Vannetzel JM, Chollet P, Misset JL, Chouaki N, Marty M, Gamelin E, Culine S, Dieras V, Mackenzie S, Spielmann M: Phase II study of oxaliplatin and fluorouracil in taxane and anthracycline-pretreated breast cancer patients. J Clin Oncol. 2002, 20: 2551-2558.CrossRefPubMed Zelek L, Cottu P, Tubiana-Hulin M, Vannetzel JM, Chollet P, Misset JL, Chouaki N, Marty M, Gamelin E, Culine S, Dieras V, Mackenzie S, Spielmann M: Phase II study of oxaliplatin and fluorouracil in taxane and anthracycline-pretreated breast cancer patients. J Clin Oncol. 2002, 20: 2551-2558.CrossRefPubMed
12.
go back to reference de Gramont AD, Vignoud J, Tournigand C, Louvet C, André T, Varette C, Raymond E, Moreau S, Le Bail N, Krulik M: Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer. 1997, 33: 214-219.CrossRefPubMed de Gramont AD, Vignoud J, Tournigand C, Louvet C, André T, Varette C, Raymond E, Moreau S, Le Bail N, Krulik M: Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer. 1997, 33: 214-219.CrossRefPubMed
13.
go back to reference Sagawa T, Sato Y, Takayama T, Kuroda H, Hirakawa M, Abe S, Iyama S, Sakamaki S, Kato J, Niitsu Y: Fifth-line chemotherapy for metastatic gastric cancer – a case responding to modified FOLFOX6. Jpn J Cancer Chemother. 2007, 34: 1467-1471. Sagawa T, Sato Y, Takayama T, Kuroda H, Hirakawa M, Abe S, Iyama S, Sakamaki S, Kato J, Niitsu Y: Fifth-line chemotherapy for metastatic gastric cancer – a case responding to modified FOLFOX6. Jpn J Cancer Chemother. 2007, 34: 1467-1471.
Metadata
Title
An effective 5-fluorouracil, levofolinate, and oxaliplatin therapy for recurrent breast cancer: a case report
Authors
Makoto Takahashi
Koichiro Niwa
Shun Ishiyama
Kiichi Sugimoto
Hiromitsu Komiyama
Yukihiro Yaginuma
Yutaka Kojima
Michitoshi Goto
Atsushi Okuzawa
Yuichi Tomiki
Kazuhiro Sakamoto
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Journal of Medical Case Reports / Issue 1/2014
Electronic ISSN: 1752-1947
DOI
https://doi.org/10.1186/1752-1947-8-234

Other articles of this Issue 1/2014

Journal of Medical Case Reports 1/2014 Go to the issue